INDUSTRY × Neoplasms × Breast × Clear all
NCT06910657 2026-03-02

IDOV-Immune for Advanced Solid Tumors

ViroMissile, Inc.

Phase 1 Recruiting
78 enrolled
NCT04485013 2026-02-18

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

Tizona Therapeutics, Inc

Phase 1 Recruiting
240 enrolled
NCT04260802 2026-01-12

A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers

Ocellaris Pharma, Inc.

Phase 1/2 Terminated
73 enrolled
NCT03899792 2026-01-06

LIBRETTO-121

Eli Lilly and Company

Phase 1/2 Active not recruiting
36 enrolled 13 charts 2 FDA
NCT05544929 2026-01-06

A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers

Novartis

Phase 1 Active not recruiting
126 enrolled
NCT06022029 2025-12-24

ON-5001

OncoNano Medicine, Inc.

Phase 1 Recruiting
168 enrolled
NCT03452774 2025-10-28

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Massive Bio, Inc.

Recruiting
50,000 enrolled
NCT03157128 2025-10-20

LIBRETTO-001

Eli Lilly and Company

Phase 1/2 Active not recruiting
857 enrolled 3 FDA
NCT05107674 2025-09-09

A Study of NX-1607 in Adults With Advanced Malignancies

Nurix Therapeutics, Inc.

Phase 1 Recruiting
345 enrolled
NCT03170960 2025-08-17

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Exelixis

Phase 1 Active not recruiting
914 enrolled
NCT05086692 2025-07-09

ABILITY-1

Medicenna Therapeutics, Inc.

Phase 1/2 Recruiting
115 enrolled